[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20080829L - Compositions and methods for controlling angiogenesis with cupredoxins - Google Patents

Compositions and methods for controlling angiogenesis with cupredoxins

Info

Publication number
NO20080829L
NO20080829L NO20080829A NO20080829A NO20080829L NO 20080829 L NO20080829 L NO 20080829L NO 20080829 A NO20080829 A NO 20080829A NO 20080829 A NO20080829 A NO 20080829A NO 20080829 L NO20080829 L NO 20080829L
Authority
NO
Norway
Prior art keywords
compositions
cupredoxins
angiogenesis
methods
peptides
Prior art date
Application number
NO20080829A
Other languages
Norwegian (no)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Rajeshwari Mehta
Brad Taylor
Tohru Yamada
Craig Beattie
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Priority claimed from US11/436,592 external-priority patent/US7381701B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20080829L publication Critical patent/NO20080829L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SAMMENDRAG Den foreliggende oppfinnelse vedrører sammensetninger omfattende cupredoxiner, og deres anvendelse for å inhibere angiogenese i mammalske celler, vev, og dyr, og særskilt angiogenesen som medfølger tumorutvikling og særskilt i mennesker. Spesifikt vedrører den foreliggende oppfinnelse sammensetninger omfattende cupredoxinet(ene), og eller peptider som er varianter, derivater eller strukturelle ekvivalenter av cupredoxiner, som bibeholder evnen til å inhibere angiogenese i mammalske celler, vev eller dyr. Disse sammensetningene kan være peptider eller farmasøytiske sammensetninger, blant andre. Sammensetningene av oppfinnelsen kan brukes for å behandle en hvilken som helst patologisk tilstand som har som et symptom eller årsak, upassende angiogenese, og særskilt upassende angiogenese relatert til tumorutvikling.SUMMARY The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and in particular the angiogenesis that accompanies tumor development and, in particular, in humans. Specifically, the present invention relates to compositions comprising the cupredoxin (s) and or peptides which are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition which has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.

NO20080829A 2005-07-19 2008-02-15 Compositions and methods for controlling angiogenesis with cupredoxins NO20080829L (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70029705P 2005-07-19 2005-07-19
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
US11/436,592 US7381701B2 (en) 2001-02-15 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
PCT/US2006/027940 WO2007024368A2 (en) 2005-07-19 2006-07-19 Compositions and methods to control angiogenesis with cupredoxins

Publications (1)

Publication Number Publication Date
NO20080829L true NO20080829L (en) 2008-04-02

Family

ID=37772089

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080829A NO20080829L (en) 2005-07-19 2008-02-15 Compositions and methods for controlling angiogenesis with cupredoxins

Country Status (10)

Country Link
EP (1) EP1904081A4 (en)
JP (1) JP2009502797A (en)
KR (1) KR20080034905A (en)
AU (1) AU2006284490A1 (en)
BR (1) BRPI0615555A2 (en)
CA (1) CA2615560A1 (en)
IL (1) IL188691A0 (en)
MX (1) MX2008000993A (en)
NO (1) NO20080829L (en)
WO (1) WO2007024368A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158574B2 (en) * 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
JP2010503409A (en) * 2006-09-14 2010-02-04 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for preventing cancer with cupredoxins
CN101600728A (en) * 2006-12-04 2009-12-09 伊利诺斯大学理事会 Use the composition and the method for cupredoxin and the DNA treatment cancer that is rich in CpG

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CN101437842A (en) * 2004-10-07 2009-05-20 阿南达·查克拉博蒂 Cupredoxin derived transport formulations and methods of use thereof
CA2608398A1 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
MX2007014597A (en) * 2005-05-20 2008-01-21 Univ Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome.
KR20080040631A (en) * 2005-05-20 2008-05-08 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Also Published As

Publication number Publication date
AU2006284490A1 (en) 2007-03-01
BRPI0615555A2 (en) 2009-07-14
EP1904081A2 (en) 2008-04-02
EP1904081A4 (en) 2008-12-03
AU2006284490A8 (en) 2008-02-28
WO2007024368A3 (en) 2007-10-11
KR20080034905A (en) 2008-04-22
WO2007024368A2 (en) 2007-03-01
IL188691A0 (en) 2008-08-07
JP2009502797A (en) 2009-01-29
MX2008000993A (en) 2008-03-19
CA2615560A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
NO20090469L (en) Substituted piperidines which increase P53 activity and use thereof
NO20052595L (en) Compositions useful as inhibitors of ROCK and other protein kinases.
NO20064976L (en) Azanidols useful as inhibitors of rock and other protein kinases
EA200870019A1 (en) LACTAMIC CONNECTIONS AND METHODS OF THEIR APPLICATION
NO20076616L (en) 17beta-HSD1 and STS inhibitors
NO20091326L (en) Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
NO20083572L (en) Thiazole compounds as protein kinase-B (PKB) inhibitors
NO20081354L (en) Double variable domain immunoglobin and methods thereof
NO20076515L (en) hydantoin
NO20084652L (en) Deazapurins useful as inhibitors of januskinases
NO20083324L (en) Multicyclic amino acid derivatives and their use
EA200700058A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF THEIR USE
DE602005023763D1 (en) PYRAZOLOA1,5-ATPYRIMIDINES SUITABLE AS INHIBITORS OF PROTEIN KINASES
NO20073140L (en) Pyrrolopyrazines and pyralopyrazines useful as inhibitors of protein kinases
DE602005020611D1 (en) COMPOSITIONS SUITED AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES
NO20080626L (en) Inhibitors of fibroblast activating protein alpha
HK1134283A1 (en) Arylsulfonamide compounds
NO20074431L (en) Pyrrolopyrimidines useful as protein kinase inhibitors
NO20084747L (en) Tetrahydropteridines useful as inhibitors of protein kinases
NO20082026L (en) Deazapurins useful as inhibitors of Janus kinases
NO20091926L (en) Anti-Notch3 Agonist Antibodies and Their Use in the Treatment of Notch3-Related Diseases
ATE524452T1 (en) SULFONAMIDES FOR TREATING CONGESTIVE HEART FAILURE, COMPOSITIONS AND USES THEREOF.
NO20092130L (en) Tricyclic heteroaryl compounds useful as inhibitors of januskinase
EA201001558A1 (en) COMPOSITIONS CONTAINING anr NOX INHIBITORS TO SUPPRESS ACTIVE FORMS OF OXYGEN
NO20075815L (en) Formulations and methods for treating amyloidosis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application